Skip to contentC
CNBX Pharmaceuticals Inc.
C
CNBXCNBX Pharmaceuticals Inc. Q3 2025 · 10-Q
Revenue$0.00$0.00— vs Q3 2024 Net Income-$59.73K-$59.73KN/M vs Q3 2024 EPS Diluted$0.00$0.00— vs Q3 2024 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
CNBX Pharmaceuticals Inc. · CIK 1343009 · Engraved from SEC EDGAR
-$40,380
N/M
Operating Cash Flowderived-$52,019N/M ended May 31, 2025 · filed Jul 14, 2025 · 44 d after period end